FR2681786A1 - Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. - Google Patents

Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. Download PDF

Info

Publication number
FR2681786A1
FR2681786A1 FR9111947A FR9111947A FR2681786A1 FR 2681786 A1 FR2681786 A1 FR 2681786A1 FR 9111947 A FR9111947 A FR 9111947A FR 9111947 A FR9111947 A FR 9111947A FR 2681786 A1 FR2681786 A1 FR 2681786A1
Authority
FR
France
Prior art keywords
muscle cells
vectors
nucleic acid
recombinant
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9111947A
Other languages
English (en)
French (fr)
Other versions
FR2681786B1 (OSRAM
Inventor
Perricaudet Michel
Briand Pascale
Stratford-Perricaudet Leslie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9417378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2681786(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9111947A priority Critical patent/FR2681786A1/fr
Priority to CA002097185A priority patent/CA2097185C/fr
Priority to EP92921684A priority patent/EP0559884B2/fr
Priority to AT92921684T priority patent/ATE192500T1/de
Priority to AU27902/92A priority patent/AU666142B2/en
Priority to DE69230993T priority patent/DE69230993T3/de
Priority to SG1996005855A priority patent/SG49081A1/en
Priority to JP50585393A priority patent/JP3487597B2/ja
Priority to DK92921684T priority patent/DK0559884T4/da
Priority to ES92921684T priority patent/ES2147553T5/es
Priority to PCT/FR1992/000898 priority patent/WO1993006223A1/fr
Publication of FR2681786A1 publication Critical patent/FR2681786A1/fr
Publication of FR2681786B1 publication Critical patent/FR2681786B1/fr
Application granted granted Critical
Priority to US09/454,737 priority patent/US6743623B2/en
Priority to GR20000401791T priority patent/GR3034094T3/el
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9111947A 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. Granted FR2681786A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9111947A FR2681786A1 (fr) 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
SG1996005855A SG49081A1 (en) 1991-09-27 1992-09-25 Viral recombinant vectors for expression in muscle cells
DK92921684T DK0559884T4 (da) 1991-09-27 1992-09-25 Rekombinante virusvektorer til ekspression i muskelceller
AT92921684T ATE192500T1 (de) 1991-09-27 1992-09-25 Rekombinante viren vektoren zur expression in muskelzellen
AU27902/92A AU666142B2 (en) 1991-09-27 1992-09-25 Viral recombinant vectors for expression in muscle cells
DE69230993T DE69230993T3 (de) 1991-09-27 1992-09-25 Rekombinante viren vektoren zur expression in muskelzellen
CA002097185A CA2097185C (fr) 1991-09-27 1992-09-25 Vecteurs recombinants viraux pour l'expression dans des cellules musculaires
JP50585393A JP3487597B2 (ja) 1991-09-27 1992-09-25 筋細胞内での発現のためのウイルス性組換え型ベクター
EP92921684A EP0559884B2 (fr) 1991-09-27 1992-09-25 Vecteurs recombinants viraux pour l'expression dans des cellules musculaires
ES92921684T ES2147553T5 (es) 1991-09-27 1992-09-25 Vectores virales recombinantes para la expresion en unas celulas musculares.
PCT/FR1992/000898 WO1993006223A1 (fr) 1991-09-27 1992-09-25 Vecteurs recombinants viraux pour l'expression dans des cellules musculaires
US09/454,737 US6743623B2 (en) 1991-09-27 1999-12-06 Viral recombinant vectors for expression in muscle cells
GR20000401791T GR3034094T3 (en) 1991-09-27 2000-08-02 Viral recombinant vectors for expression in muscle cells.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9111947A FR2681786A1 (fr) 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.

Publications (2)

Publication Number Publication Date
FR2681786A1 true FR2681786A1 (fr) 1993-04-02
FR2681786B1 FR2681786B1 (OSRAM) 1995-05-12

Family

ID=9417378

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9111947A Granted FR2681786A1 (fr) 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.

Country Status (12)

Country Link
EP (1) EP0559884B2 (OSRAM)
JP (1) JP3487597B2 (OSRAM)
AT (1) ATE192500T1 (OSRAM)
AU (1) AU666142B2 (OSRAM)
CA (1) CA2097185C (OSRAM)
DE (1) DE69230993T3 (OSRAM)
DK (1) DK0559884T4 (OSRAM)
ES (1) ES2147553T5 (OSRAM)
FR (1) FR2681786A1 (OSRAM)
GR (1) GR3034094T3 (OSRAM)
SG (1) SG49081A1 (OSRAM)
WO (1) WO1993006223A1 (OSRAM)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667791A4 (en) * 1991-08-22 1996-05-08 Univ Leland Stanford Junior ISOLATION, GROWTH, DIFFERENTIATION AND GENE TECHNOLOGICAL MANIPULATION OF HUMAN MUSCLE CELLS.
EP0919625A3 (fr) * 1993-05-28 1999-08-18 Transgene S.A. Adénovirus défectifs et lignées de complémentation correspondantes
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US6939862B2 (en) 1997-06-30 2005-09-06 Aventis Pharma S.A. Method for transferring nucleic acid into striated muscles
US7772003B2 (en) 2001-08-29 2010-08-10 Aventis Pharma S.A. Lipid derivatives of aminoglycosides
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5457294A (en) * 1992-10-29 1994-05-24 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
CA2149771A1 (en) * 1992-11-18 1994-05-26 Jeffrey M. Leiden Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US6080569A (en) 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US20020136708A1 (en) 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
DE69434486T2 (de) * 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
FR2718749B1 (fr) * 1994-04-18 1996-05-31 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
KR100356615B1 (ko) * 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6974694B2 (en) 1995-06-07 2005-12-13 Advec, Inc. Adenoviruses for control of gene expression
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
PT1944371E (pt) 1998-05-01 2015-07-13 Novartis Ag Antigénios e composições da neisseria meningitidis
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
AU1316200A (en) 1998-10-15 2000-05-01 Chiron Corporation Metastatic breast and colon cancer regulated genes
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1961813B1 (en) 1998-12-16 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
US6673601B1 (en) 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
EP1721982B1 (en) 1999-04-15 2013-04-10 Boehringer Ingelheim Vetmedica GmbH Chimeric lyssavirus nucleic acids and polypeptides
EP2290083B1 (en) 1999-04-30 2014-08-20 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2003520248A (ja) 2000-01-17 2003-07-02 カイロン エセ．ピー．アー． Ｎ．ｍｅｎｉｎｇｉｔｉｄｉｓ血清型ｂ外膜タンパク質を含む外膜小胞（ｏｍｖ）ワクチン
EP1790660B1 (en) 2000-02-28 2012-06-20 Novartis Vaccines and Diagnostics S.r.l. Heterologous expression of neisserial proteins
US7238672B1 (en) 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
JPWO2002031138A1 (ja) * 2000-10-06 2004-02-19 株式会社ディナベック研究所 骨格筋に外来遺伝子を導入するためのパラミクソウイルスベクター
NZ594877A (en) 2000-10-27 2012-07-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005093064A1 (ja) 2004-03-29 2005-10-06 Galpharma Co., Ltd. 新規ガレクチン９改変体タンパク質及びその用途
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US8999944B2 (en) 2005-01-20 2015-04-07 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
US8026354B2 (en) 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008116116A2 (en) 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
EP2658567A4 (en) 2010-12-28 2014-09-24 Univ Rochester METHOD FOR MODIFYING INSULIN SIGNAL TRANSMISSION BY BILIVERDINREDUCTASE (BVR) AND BVR-DERIVED PEPTIDES
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
EP2908853B1 (en) 2012-10-21 2018-12-05 University Of Rochester Thy1 (cd90) as a therapy to control adipose tissue accumulation
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185573A1 (fr) * 1984-11-20 1986-06-25 Institut Pasteur Expression et sécrétion de polypeptides dans des eucaryotes, sous contrôle d'un promoteur d'adénovirus
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
WO1988000971A1 (en) * 1986-08-01 1988-02-11 Commonwealth Scientific And Industrial Research Or Recombinant vaccine
WO1990013640A1 (en) * 1989-05-01 1990-11-15 The University Of Notre Dame Du Lac Methods and materials for expression of human plasminogen in a eukaryotic cell system
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185573A1 (fr) * 1984-11-20 1986-06-25 Institut Pasteur Expression et sécrétion de polypeptides dans des eucaryotes, sous contrôle d'un promoteur d'adénovirus
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLLOQUE INSERM (HUMAN GENE TRANSFER, INTERNATIONAL WORKSHOP) vol. 219, 11 Avril 1991, PARIS, FRANCE pages 51 - 61; STRATFORD-PERRICAUDET, L. & PERRICAUDET, M.: 'Gene transfer into animals : the promise of adenovirus' *
COLLOQUE INSERM (HUMAN GENE TRANSFER. INTERNATIONAL WORKSHOP) vol. 219, 11 Avril 1991, PARIS, FRANCE pages 271 - 272; QUANTIN, B. ET AL.: 'Adenovirus as an expression vector in muscle cells application to dystrophin' *
SCIENCE. vol. 252, no. 5004, 19 Avril 1991, LANCASTER, PA US pages 431 - 434; ROSENFELD, M.A. ET AL.: 'Adenovirus-mediated transfer of a recombinant alpha1-antitrypsin gene to the lung epithelium in vivo' specially figure 1 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667791A4 (en) * 1991-08-22 1996-05-08 Univ Leland Stanford Junior ISOLATION, GROWTH, DIFFERENTIATION AND GENE TECHNOLOGICAL MANIPULATION OF HUMAN MUSCLE CELLS.
EP0919625A3 (fr) * 1993-05-28 1999-08-18 Transgene S.A. Adénovirus défectifs et lignées de complémentation correspondantes
EP0919624A3 (fr) * 1993-05-28 1999-08-18 Transgene S.A. Adénovirus défectifs et lignées de complémentation correspondantes
EP0919626A3 (fr) * 1993-05-28 1999-08-18 Transgene S.A. Adénovirus défectifs et lignées de complémentation correpondantes
US6939862B2 (en) 1997-06-30 2005-09-06 Aventis Pharma S.A. Method for transferring nucleic acid into striated muscles
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US7772003B2 (en) 2001-08-29 2010-08-10 Aventis Pharma S.A. Lipid derivatives of aminoglycosides
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery

Also Published As

Publication number Publication date
WO1993006223A1 (fr) 1993-04-01
ES2147553T5 (es) 2004-11-16
AU666142B2 (en) 1996-02-01
DK0559884T4 (da) 2004-08-02
EP0559884A1 (fr) 1993-09-15
CA2097185C (fr) 2007-07-24
CA2097185A1 (fr) 1993-03-28
DE69230993D1 (de) 2000-06-08
DE69230993T3 (de) 2004-12-16
GR3034094T3 (en) 2000-11-30
EP0559884B2 (fr) 2004-04-07
AU2790292A (en) 1993-04-27
JP3487597B2 (ja) 2004-01-19
DK0559884T3 (da) 2000-10-02
SG49081A1 (en) 1998-05-18
ATE192500T1 (de) 2000-05-15
FR2681786B1 (OSRAM) 1995-05-12
ES2147553T3 (es) 2000-09-16
DE69230993T2 (de) 2000-11-30
JPH06502771A (ja) 1994-03-31
EP0559884B1 (fr) 2000-05-03

Similar Documents

Publication Publication Date Title
EP0559884B1 (fr) Vecteurs recombinants viraux pour l'expression dans des cellules musculaires
EP0752004B1 (fr) Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf)
FR2727867A1 (fr) Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
EP0775213B1 (fr) Adenovirus comprenant un gene codant pour la glutathion peroxydase
JP2004313198A (ja) 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入
CA2291590A1 (fr) Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
EP0687184B1 (fr) Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires
JPH10501402A (ja) 肝臓特異的遺伝子治療のためのベクター
US6743623B2 (en) Viral recombinant vectors for expression in muscle cells
CA2271437A1 (fr) Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies
US6099831A (en) Viral recombinant vectors for expression in muscle cells
EP0750675A1 (fr) ADENOVIRUS RECOMBINANTS CODANT POUR LE FACTEUR DE CROISSANCE DES FIBROBLASTES ACIDES (aFGF)
EP0763116B1 (fr) Virus recombinants, preparation et utilisation en therapie genique
FR2717496A1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
WO2025140399A9 (en) Gene editing systems and methods for treating cardiovascular disease
CA2343922A1 (fr) Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
FR2717497A1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2726575A1 (fr) Virus recombinants, preparation et utilisation en therapie genique

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
ST Notification of lapse